selected scholarly activity
-
chapters
- Oral direct factor xa inhibitors. 307-325. 2016
- Venous Thromboembolism: Pathophysiology, Diagnosis, and Prophylaxis. 306-316. 2012
- Emerging oral antiplatelet receptor inhibitors. 119-126. 2008
-
conferences
- Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF. European Heart Journal Open. oead051. 2023
- Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis. Blood. 1438-1438. 2016
- Improved Treatment Satisfaction Independent of Stroke and Bleeding Risk Among Patients Transitioned From a Vitamin K Antagonist to Rivaroxaban: A XANTUS-ACTS Analysis. Circulation. 2016
- CLINICAL CHARACTERISTICS AND OUTCOMES OF 'EARLY SWITCHERS': A SUBSET OF PATIENTS FROM XALIA, A PROSPECTIVE NON-INTERVENTIONAL STUDY. American Journal of Hematology. E430-E430. 2016
- PREDICTORS OF MAJOR BLEEDING DURING WARFARIN INTERRUPTION FOR INVASIVE PROCEDURES: ANALYSIS OF THE BRIDGE TRIAL. American Journal of Hematology. E391-E391. 2016
- Predictors of major bleeding in patients with atrial fibrillation treated with rivaroxaban in XANTUS: findings from a real-world prospective study. European Heart Journal. 512-513. 2016
- Subgroup analysis of patients with concomitant pulmonary embolism in XALIA, a non-interventional study of rivaroxaban in routine treatment of deep vein thrombosis. European Heart Journal. 817-818. 2016
- Vitamin K antagonist control for patients with nonvalvular atrial fibrillation in Eastern and Southeastern Asia: an analysis of event rates from GARFIELD-AF. European Heart Journal. 1007-1008. 2016
- Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis. Blood. 2015
- Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in GARFIELD-AF. European Heart Journal. 745-746. 2015
- Stroke, major bleeding and mortality in newly diagnosed atrial fibrillation with moderate-to-severe chronic kidney disease: results from GARFIELD-AF. European Heart Journal. 987-987. 2015
- Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery (the bridge trial). Journal of Thrombosis and Haemostasis. 83-84. 2015
- Quality of vitamin k antagonist control and 1-year outcomes: a global perspective from the garfield-af registry. Journal of Thrombosis and Haemostasis. 130-130. 2015
- Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Journal of Thrombosis and Haemostasis. 139-139. 2015
- Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial. Blood. 2014
- Truly low-risk patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke: 1-year outcomes from the GARFIELD Registry. European Heart Journal. 1108-1108. 2014
- RIVAROXABAN FOR THROMBOPROPHYLAXIS AFTER NON-ELECTIVE ORTHOPAEDIC SURGERY IN ROUTINE CLINICAL PRACTICE. American Journal of Hematology. E73-E74. 2014
- RIVAROXABAN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT SURGERY: COMPARISON OF OUTCOMES OF THE XAMOS AND RECORD STUDIES. American Journal of Hematology. E74-E75. 2014
- One-year outcomes in new versus permanent atrial fibrillation: insights from the prospective, international GARFIELD registry. European Heart Journal. 954-954. 2013
- Twelve-month outcomes in paroxysmal versus permanent atrial fibrillation: data from the prospective, international GARFIELD registry. European Heart Journal. 738-738. 2013
- Dalteparin sodium for the long-term management of venous thromboembolism in cancer patients. The DALTECAN Study. Journal of Thrombosis and Haemostasis. 18-19. 2013
- Venous thromboembolism: an annual European Union 27 cost-of-illness model for the burden of the disease. Journal of Thrombosis and Haemostasis. 258-258. 2013
- Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies. Blood. 500-500. 2012
- Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies. Blood. 2012
- C0129 Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature. Thrombosis Research. S111-S111. 2012
- Antithrombotic therapy for stroke prevention in patients with newly diagnosed atrial fibrillation and a history of acute coronary syndrome: the Global Anticoagulant Registry in the FIELD (GARFIELD). European Heart Journal. 1081-1081. 2012
- Impact of renal function on use of antithrombotic therapy in atrial fibrillation: real-world perspective from the global anticoagulant registry in the FIELD registry. European Heart Journal. 967-968. 2012
- Regional differences in the use of antithrombotic therapy for stroke prevention in atrial fibrillation: European and Asian insights from the Global Anticoagulant Registry in the FIELD (GARFIELD). European Heart Journal. 685-685. 2012
- A Pooled Analysis of Surgical Complications: Results from the RECORD Program.. Journal of The American Geriatrics Society. S242-S242. 2012
- XAMOS: a non-interventional study comparing oral rivaroxaban with conventional regimens for thromboprophylaxis after major orthopaedic surgery of the hip and knee. British Journal of Haematology. 9-10. 2012
- Rivaroxaban: un anti-thrombotique original. Archives des Maladies du Coeur et des Vaisseaux - Pratique. 13-15. 2012
- Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO. Blood. 206-206. 2011
- Venous Thromboembolism Validation Study of the IMPROVE Risk Assessment Models in the Medical Patient (VTE-VALOURR). Blood. 1803-1804. 2011
- Canadian cardiovascular society antiplatelet guidelines. Stroke. E592-E592. 2011
- 3001 POSTER DISCUSSION Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups. European Journal of Cancer. S222-S222. 2011
- Direct factor Xa and thrombin inhibitors: clinical trial update. Journal of Thrombosis and Haemostasis. 499-499. 2011
- Onyx-3, a double-blind comparison of once- or twice-daily dosing with YM150 (30 or 60 mg daily) for preventing venous thromboembolism after elective hip arthroplasty. Journal of Thrombosis and Haemostasis. 855-855. 2011
- Venous thromboembolism validation study of the improve risk assessment models in the medical patient (VTE-VALOURR). Journal of Thrombosis and Haemostasis. 402-403. 2011
- XAMOS: A non-interventional study of rivaroxaban in the prophylaxis of venous thromboembolism after hip or knee surgery. Journal of Thrombosis and Haemostasis. 961-961. 2011
- The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. Journal of Clinical Oncology. 2011
- The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. Journal of Clinical Oncology. 2011
- The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery. Blood. 188-188. 2010
- Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a phase II study. European Heart Journal. 173-173. 2010
- Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.. Blood. 76-76. 2009
- Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban. Blood. 828-828. 2009
- Quantitative Benefit-Risk Assessment of Rivaroxaban for the Prevention of Venous Thromboembolism.. Blood. 75-76. 2009
- D-dimer testing, thrombophilia screening and recurrences in patients with venous thromboembolism: a 6-year follow-up. European Heart Journal. 312-312. 2009
- New approaches to anticoagulation: Oral factor Xa inhibitors. Thrombosis and Haemostasis. 16-20. 2009
- Pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery. British Journal of Haematology. 4-4. 2009
- Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art. EUROPEAN INSTRUCTIONAL LECTURES, VOL 9, 2009. 29-38. 2009
- A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding. Blood. 19-20. 2008
- A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effects of Specified Co-Medications. Blood. 693-693. 2008
- Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4. Blood. 19-19. 2008
- The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely III Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study. Blood. 167-167. 2008
- The Unmet Need for Extended Thromboprophylaxis in Acutely III Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM. Blood. 692-692. 2008
- Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study. Blood. 165-165. 2008
- A meta-analysis of three pivotal studies of rivaroxaban for thromboprophylaxis after orthopaedic surgery: effect on symptomatic venous thromboembolism, all-cause mortality and bleeding. European Heart Journal. 827-827. 2008
- EFFECT OF FONDAPARINUX 2.5 MG ONCE DAILY ON ALL CAUSE MORTALITY: A META-ANALYSIS OF THROMBOPROPHYLAXIS TRIALS. Haematologica. 146-146. 2008
- PHARMACOKINETICS (PK) OF SUBCUTANEOUS FONDAPARINUX 1.5 MG IN PATIENTS WITH MODERATE RENAL IMPAIREMENT (MRI). Haematologica. 157-157. 2008
- The oral, direct factor Xa inhibitor rivaroxaban vs enoxaparin for prevention of venous thromboembolism after total knee replacement: RECORD3. British Journal of Haematology. 65-65. 2008
- Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.. Blood. 1863-1863. 2007
- Extended-duration enoxaparin for venous thromboembolism prophylaxis in acutely ill medical patients: An evaluation of the EXCLAIM study based on a recently recommended composite efficacy endpoint. Blood. 554A-554A. 2007
- Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.. Blood. 309-309. 2007
- Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.. Blood. 308-308. 2007
- The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.. Blood. 1862-1862. 2007
- Development of an improved strategy for perioperative bridging of anticoagulation: Predictors of wound hematoma following surgery for permanent pacemakers and implantable defibrillators. Canadian Journal of Cardiology. 174C-174C. 2007
- Effect of fondaparinux 2.5 mg once daily on all cause mortality: a meta-analysis of thromboprophylaxis trials. European Heart Journal. 188-188. 2007
- Fondaparinux reduces symptomatic pulmonary embolism and death in patients hospitalized with congestive heart failure: a sub-analysis of the randomized ARTEMIS trial. European Heart Journal. 50-50. 2007
- Combined pharmacologic and mechanical prophylaxis for the prevention of venous thromboembolism after major abdominal surgery: Results of the APOLLO study. Diseases of the Colon and Rectum. 744-745. 2006
- Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: A meta-analysis of the randomized trials. Journal of the American College of Cardiology. 228A-229A. 2006
- Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of venous thromboembolism after major abdominal surgery: The randomized APOLLO study.. Blood. 85A-85A. 2005
- Rates of clinically apparent venous thromboembolism and death resulting from pulmonary embolism among unselected hospitalized acutely ill medical patients versus rates predicted from clinical studies.. Blood. 463A-463A. 2005
- Thromboprophylaxis after orthopaedic surgery with an oral, direct factor Xa inhibitor:: Pooled results of two phase Iib clinical trials.. Blood. 85A-85A. 2005
- VENUS - A study to validate centrally adjudicated venous ultrasound against venography after major orthopaedic surgery.. Blood. 86A-86A. 2005
- Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical heart valves on long-term oral, anticoagulants: Results from the REGIMEN registry. Journal of the American College of Cardiology. 352A-352A. 2005
- A Prospective Registry on Venous Thromboembolic Events: Findings from PROVE.. Blood. 1769-1769. 2004
- Benefit of fondaparinux in medical patients: A subgroup analysis.. Blood. 106B-106B. 2004
- Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: Results from the REGIMEN registry.. Blood. 203A-204A. 2004
- Enoxaparin Is Effective and Safe as Bridging Anticoagulation in Patients with a Mechanical Prosthetic Heart Valve who Require Temporary Interruption of Warfarin because of Surgery or an Invasive Procedure.. Blood. 703-703. 2004
- Identification of Medical Patients Who Should Receive Venous Thromboembolism Prophylaxis.. Blood. 1786-1786. 2004
- Perioperative Bridging Therapy with Enoxaparin in Patients Requiring Interruption of Long-Term Oral Anticoagulant Therapy: A Multicenter Cohort Study.. Blood. 1761-1761. 2004
- The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous thromboembolism prophylaxis practices in acutely ill medical patients. Blood. 488A-488A. 2004
- Early vs delayed initiation of fondaparinux prophylaxis to prevent postoperative pulmonary embolism: A clinical endpoint study. Chest. 783S-783S. 2004
- Conclusion. Blood Coagulation and Fibrinolysis. 289-299. 2004
- Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients.. Blood. 321A-321A. 2003
- Fondaparinux for the prevention of VTE in acutely ill medical patients.. Blood. 15A-15A. 2003
- IMPROVE, a multinational observational cohort study of practices in prevention of venous thromboembolism in acutely ill medical patients: A comparison with clinical study patient populations.. Blood. 319A-319A. 2003
- Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial.. Blood. 165A-166A. 2003
- Registry of patients on chronic oral anticoagulant therapy requiring (Low-Molecular-Weight) heparin for an elective surgical intervention or procedure (REGIMEN): Rationale, design, and interim analysis of a large, long-term, multicenter cohort study.. Blood. 323A-323A. 2003
- The EXCLAIM study: Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with restricted mobility.. Blood. 125B-125B. 2003
- Utilization of venous thromboprophylaxis in acutely ill medical patients in Canada: Results from the Canadian Registry (CURVE).. Blood. 498A-498A. 2003
- Venous ultrasound: An alternative to venography for evaluation of Dalteparin prophylaxis in 3,706 medically ill hospitalized patients.. Blood. 324A-325A. 2003
- Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders. American Journal of Health-System Pharmacy. S20-S24. 2003
- Bleeding complications of thromboprophylaxis after hip replacement: A systematic review.. Blood. 505A-505A. 2002
- Effect of age on the benefit-risk ratio of fondaparinux thromboprophylaxis in patients undergoing major orthopedic surgery.. Blood. 278A-278A. 2002
- Extended thromboprophylaxis in acutely ill medical patients with prolonged immobilisation: The EXCLAIM study.. Blood. 127B-127B. 2002
- Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism following hip fracture surgery.. Blood. 83A-83A. 2002
- Low-intensity (INR 1.5-1.9) versus conventional-intensity (INR 2.0-3.0) anticoagulation for extended treatment of unprovoked VTE: A randomized double blind trial.. Blood. 150A-150A. 2002
- Prospective Multicentre trial of bridging therapy with dalteparin for patients who require temporary discontinuation of OAC for prosthetic valves or high risk atrial fibrillation.. Blood. 149A-149A. 2002
- Venous thromboembolism risk assessment in medical patients.. Blood. 280A-280A. 2002
- Consistency of fondaparinux superiority for venous thromboembolism prevention in orthopedic surgery according to different composite efficacy. Pharmacotherapy. 1344-1345. 2002
- Consistency of fondaparinux superiority over enoxaparin in prevention of venous thromboembolism in orthopaedic surgery according to different composite efficacy endpoints. 7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION. 289-292. 2002
- Effect on efficacy and safety of the timing of the first administration of fondaparinux (Arixtra (R)) in the prophylaxis of venous thromboembolism following major orthopaedic surgery. 7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION. 301-304. 2002
- Efficacy and safety of fondaparinux in the thromboprophylaxis of venous thromboembolism following major orthopaedic surgery according to the recommendations for use in the United States. 7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION. 297-300. 2002
- Preface. Seminars in Thrombosis and Hemostasis. 1-4. 2002
- Role of the duration of fondaparinux (Arixtra((R))) prophylaxis in preventing venous thromboembolism following major orthopaedic surgery. 7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION. 293-296. 2002
- Benefit of enoxaparin in medical patients. A subgroup analysis.. Blood. 266A-266A. 2001
- Current management of venous thromboembolism prophylaxis after major orthopedic surgery in North America and Europe: Lessons from the pentasaccharide (fondaparinux, Arixtra (R)) database.. Blood. 269A-269A. 2001
- Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra (R)) administration in the prevention of venous thromboembolism (VTE) after major orthopedic surgery.. Blood. 266A-266A. 2001
- Four weeks versus 12 weeks of anticoagulation for a first episode of venous thromboembolism (VTE) provoked by a transient-risk factor: A randomized double-blind trial.. Blood. 448A-448A. 2001
- Pentasaccharide (fondaparinux, Arixtra (R)) versus enoxaparin for the prevention of venous thromboembolism (VTE) in major orthopedic surgery: Subgroup analyses on efficacy.. Blood. 266A-266A. 2001
- Relevance of systematic venographic outcomes in venous thromboembolism (VTE) prophylaxis studies: Lessons from the pentasaccharide (fondaparinux, Arixtra (R)) clinical program.. Blood. 272A-272A. 2001
- Overview of the clinical results of pentasaccharide in major orthopedic surgery. Haematologica. 59-62. 2001
- Looking forward in the treatment of deep-vein thrombosis. Seminars in Hematology. 49-57. 2001
- A comparison of the impact of practice patterns on the outcomes of patients with acute coronary syndromes in the USA and Canada: Post hoc analysis of ESSENCE and TIMI 11B. Journal of the American College of Cardiology. 359A-359A. 2001
- Angiology in women. Phlebolymphology. 61-65. 2000
- Temporary discontinuation of oral anticoagulants: Role of low molecular weight heparin (dalteparin). Circulation. 826-826. 2000
- Antithrombotic therapy and valve replacement. Annales de Cardiologie et d'Angeiologie. 146-147. 2000
- Antithrombotic therapy in coronary artery disease. Annales de Cardiologie et d'Angeiologie. 137-145. 2000
- Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Annales de Cardiologie et d'Angeiologie. 107-109. 2000
- Atrial fibrillation. Annales de Cardiologie et d'Angeiologie. 148-149. 2000
- Mortality reduction with low molecular weight heparin thromboprophylaxis in acutely ill medical patients: The MEDENOX trial.. Blood. 31A-31A. 1999
- Prophylaxis of venous thromboembolism in acute medical patients with enoxaparin: An international, randomized double-blind, placebo-controlled trial. Circulation. 619-619. 1999
- The benefit of enoxaparin in Q-Wave myocardial infarction: A sub-study of the TIMI 11B and ESSENCE meta-analysis. Circulation. 792-792. 1999
- Treatment benefit of enoxaparin in unstable Angina/non-Q wave myocardial infarction is maintained at one year followup in TIMI 11B. Circulation. 497-497. 1999
- Clinical trials of low molecular weight heparins. European Heart Journal, Supplement. R18-R27. 1999
- Oral anticoagulant therapy (OAT) following heart valve replacement (HVR): Comparison of a daily fixed 2.5 mg with a 5 mg, INR adjusted, dose. Thrombosis and Haemostasis. 549-550. 1999
- Predictors of the initial response to warfarin in patients starting oral anticoagulant therapy following heart valve replacement. Thrombosis and Haemostasis. 422-422. 1999
- Prophylaxis of venous thromboembolism in acute medical patients with enoxaparin: An international, randomized, double-blind, placebo-controlled trial. Thrombosis and Haemostasis. 685-685. 1999
- Temporary discontinuation of oral anticoagulants: Role of low molecular weight heparin (dalteparin). Thrombosis and Haemostasis. 62-63. 1999
- Antithrombotic therapy in the new millennium - the role of low-molecular-weight heparin. SAMJ - South African Medical Journal. C151-C155. 1999
- Enoxaparin for the acute and chronic management of unstable angina non-Q wave myocardial infarction: Results of TIMI 11B. Circulation. 504-504. 1998
- Randomized comparison of moderate (INR 3.0-3.5) with low intensity (INR 2.0-3.5) anticoagulant therapy in patients with prosthetic heart valves treated with aspirin (100 mg/day).. Circulation. 768-768. 1998
- Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial. American Journal of Cardiology. 19L-24L. 1998
- Accuracy and clinical utility of anticoagulation induction using a computer generated system compared with manual dosing in hospitalized patients. Thrombosis Research. S79-S80. 1998
- Fasting plasma homocysteine levels do not predict the occurrence of deep vein thrombosis after elective hip replacement surgery. Thrombosis Research. S17-S18. 1998
- The role of coagulation factors II, V, VII, and X in the response to oral anticoagulants in patients following heart valve replacement. Thrombosis Research. S80-S81. 1998
- Management of the initial phase of warfarin treatment: Retrospective analysis of post-operative heart valve replacement patients compared with nonsurgical patients.. Blood. 3199-3199. 1997
- The value of bilateral venous compression ultrasonography in patients with suspected pulmonary embolism (PE).. Blood. 1303-1303. 1997
- Successors to heparin: New antithrombotic agents. American Heart Journal. s71-s77. 1997
- Editorial. American Journal of Cardiology. 1E-1E. 1997
- Etiology of Stroke. Stroke. 1501-1506. 1997
- Optimal Intensity for Oral Anticoagulation in Patients with Prosthetic Heart Valves. Hamostaseologie. 158-160. 1997
- Blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease ''the ESSENCE trial''. Thrombosis and Haemostasis. S1528-S1528. 1997
- Prediction of deep vein thrombosis after elective hip surgery by preoperative haemostatic tests: The ECAT DVT study. Thrombosis and Haemostasis. OC742-OC742. 1997
- Randomized comparison of anticoagulant control by a computer generated system with a manual system. Thrombosis and Haemostasis. P2858-P2858. 1997
- Hemorrhage incidence with low molecular weight heparin vs unfractionated heparin in patients with unstable angina or non-Q-wave myocardial infarction. Journal of the American College of Cardiology. 3335-3335. 1997
- The value of the SimpliRed(R) D-dimer in a prospective management study of patients with suspected pulmonary embolism (PE).. Blood. 137-137. 1996
- Use of a clinical model in a prospective management study of patients with suspected pulmonary embolism (PE).. Blood. 2490-2490. 1996
- Double blind comparison of aspirin with warfarin following bioprosthetic heart valve replacement.. Circulation. 3802-3802. 1996
- Primary end point analysis from the ESSENCE trial: Enoxaparin vs unfractionated heparin in unstable angina and non-Q wave infarction.. Circulation. 3240-3240. 1996
- EFFECTS OF ORAL ANTICOAGULANTS ON MORTALITY, REINFARCTION AND STROKE AFTER MYOCARDIAL-INFARCTION. Circulation. 1632-1632. 1995
- COMPRESSION ULTRASOUND FOR THE DIAGNOSTIC MANAGEMENT OF CLINICALLY SUSPECTED DEEP-VEIN THROMBOSIS. Thrombosis and Haemostasis. 1098-1098. 1995
- LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) AND COMPRESSION STOCKINGS IN THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) IN NEUROSURGERY. Thrombosis and Haemostasis. 973-973. 1995
- RAPID FORMAT ASSAY FOR THE DETECTION OF ANTISTREPTOKINASE ANTIBODY IN HUMAN BLOOD. Clinical Chemistry. S91-S91. 1995
- Concluding remarks. European Heart Journal. 38-39. 1995
- Thrombolytic therapy in venous thrombosis and pulmonary embolism. Fibrinolysis and Proteolysis. 237-244. 1994
- ESTIMATION OF RESISTANCE TO STREPTOKINASE - A PRELIMINARY-REPORT OF A RAPID BEDSIDE TEST. Circulation. 154-154. 1993
- A RANDOMIZED TRIAL COMPARING THE ACTIVATED THROMBOPLASTIN TIME WITH THE HEPARIN ASSAY TO MONITOR HEPARIN-THERAPY IN PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM REQUIRING LARGE DAILY DOSES OF HEPARIN. Thrombosis and Haemostasis. 1122-1122. 1993
- A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING A LOW-MOLECULAR-WEIGHT HEPARINOID, ORGARAN, WITH ASPIRIN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING SURGERY FOR HIP FRACTURE. Thrombosis and Haemostasis. 1116-1116. 1993
- COLOR DOPPLER VS REAL-TIME ULTRASONOGRAPHY IN THE DIAGNOSIS OF POSTOPERATIVE ASYMPTOMATIC DVT. Thrombosis and Haemostasis. 1361-1361. 1993
- CONTRAST-MEDIA INDUCES THROMBIN GENERATION DURING PTCA. Thrombosis and Haemostasis. 1014-1014. 1993
- CONTROL OF ANTICOAGULANT-THERAPY - A CROSS CANADA SURVEY. Thrombosis and Haemostasis. 677-677. 1993
- OPTIMAL DURATION OF ORAL ANTICOAGULANT-THERAPY - A RANDOMIZED TRIAL COMPARING 4 WEEKS WITH 3 MONTHS OF WARFARIN IN PATIENTS WITH PROXIMAL DEEP-VEIN THROMBOSIS (DVT). Thrombosis and Haemostasis. 982-982. 1993
- ANTITHROMBOTIC THERAPY FOLLOWING HEART-VALVE REPLACEMENT. THROMBOSIS AND ITS MANAGEMENT. 182-187. 1993
- A PHASE-II STUDY OF HIRULOG IN THE PREVENTION OF VENOUS THROMBOSIS AFTER MAJOR HIP OR KNEE SURGERY. Circulation. 409-409. 1992
- A DOUBLE-BLIND RANDOMIZED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID VERSUS UNFRACTIONATED HEPARIN IN THE PREVENTION OF DEEP-VEIN THROMBOSIS IN PATIENTS WITH THROMBOTIC STROKE. Thrombosis and Haemostasis. 753-753. 1991
- DETECTION OF PREVIOUS DEEP-VEIN THROMBOSIS WITH VENOUS DOPPLER AND PHOTOPLETHYSMOGRAPHY. Clinical Research. A325-A325. 1989
- A RANDOMIZED TRIAL COMPARING GRADUATED COMPRESSION STOCKINGS ALONE OR GRADUATED COMPRESSION STOCKINGS PLUS INTERMITTENT PNEUMATIC COMPRESSION WITH CONTROL IN THE PREVENTION OF DEEP-VEIN THROMBOSIS IN NEUROSURGICAL PATIENTS. Arteriosclerosis. A675-A675. 1988
- OPTIMAL LEVEL OF ANTICOAGULATION FOLLOWING TISSUE VALVE-REPLACEMENT - A RANDOMIZED TRIAL. Circulation. 519-519. 1987
- A DOUBLE-BLIND RANDOMIZED TRIAL OF ORG-10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN THE PREVENTION OF DEEP-VEIN THROMBOSIS IN PATIENTS WITH THROMBOTIC STROKE. Thrombosis and Haemostasis. 123-123. 1987
- RANDOMIZED CONTROLLED TRIAL OF PK-10169 LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) FOR VENOUS THROMBOSIS PROPHYLAXIS AFTER ELECTIVE HIP-SURGERY. Circulation. 235-235. 1986
- CLINICAL-TRIALS WITH LOW-MOLECULAR-WEIGHT HEPARIN IN VENOUS THROMBOSIS. Thrombosis Research. 67-67. 1986
- A RANDOMIZED CONTROLLED TRIAL OF INTRAVENOUS HEPARIN FOR THE PREVENTION OF STROKE PROGRESSION IN ACUTE PARTIAL THROMBOTIC STROKE. Circulation. 134-134. 1985
- A RANDOMIZED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR FOR THE TREATMENT OF PROXIMAL DEEP-VEIN THROMBOSIS. Circulation. 193-193. 1985
- SYSTEMIC FIBRINOLYSIS IN VENOUS THROMBOSIS PATIENTS TREATED WITH RECOMBINANT TISSUE-TYPEPLASMINOGEN ACTIVATOR. Thrombosis and Haemostasis. 174-174. 1985
- THE ROLE OF THE LIPOXYGENASE PATHWAY IN THE MECHANISM OF ACTION OF NAFAZATROM. Thrombosis and Haemostasis. 242-242. 1985
- Logistics of double-blinding a randomized trial of intravenous vs. subcutaneous heparin for the treatment of venous thrombosis. Contemporary Clinical Trials. 300-300. 1984
- INTRAVENOUS UROKINASE (UK) AND STREPTOKINASE (SK) IN ACUTE MYOCARDIAL-INFARCTION (AMI) - EVALUATION BY CK EVOLUTION AND ANGIOGRAPHY. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 8-8. 1984
- SUSTAINED THERAPEUTIC ANTICOAGULATION WITH SUBCUTANEOUS HEPARIN FOR THE PRIMARY-TREATMENT OF VENOUS THROMBOSIS. Clinical Pharmacology and Therapeutics. 268-268. 1984
- SUSTAINED THERAPEUTIC HEPARINIZATION BY SUBCUTANEOUS ADMINISTRATION FOR THE PRIMARY-TREATMENT OF ACUTE VENOUS THROMBOSIS. Circulation. 360-360. 1984
- SYSTEMIC LYTIC EFFECTS AND COAGULATION CHANGES WITH INTRAVENOUS THROMBOLYTIC THERAPY IN EVOLVING MYOCARDIAL-INFARCTION. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 11-11. 1984
- A RANDOMIZED TRIAL OF DIAGNOSTIC STRATEGIES FOR SYMPTOMATIC DEEP-VEIN THROMBOSIS. Thrombosis and Haemostasis. 160-160. 1983
- A RANDOMIZED TRIAL OF SEQUENTIAL PNEUMATIC LIMB COMPRESSION IN THE PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING ELECTIVE HIP-SURGERY. Thrombosis and Haemostasis. 66-66. 1983
- A ROLE FOR LUNG-SCANNING EARLY IN THE MANAGEMENT OF PATIENTS WITH PROXIMAL DEEP VENOUS THROMBOSIS. Circulation. 267-267. 1983
- FAILURE OF SULOCTIDIL TO PREVENT DEEP VENOUS THROMBOSIS IN NEUROSURGICAL PATIENTS. Thrombosis and Haemostasis. 248-248. 1983
- OUTCOME OF ABNORMAL IMPEDANCE PLETHYSMOGRAPHY RESULTS IN PATIENTS WITH PROXIMAL VEIN-THROMBOSIS - FREQUENCY OF RETURN TO NORMAL. Thrombosis and Haemostasis. 152-152. 1983
- PLATELET SURVIVAL AND BETATHROMBOGLOBULIN AFTER HETEROGRAFT MITRAL-VALVE REPLACEMENT - EFFECT OF SULOCTIDIL. Thrombosis and Haemostasis. 63-63. 1983
- PULMONARY ANGIOGRAPHY, VENTILATION SCANNING AND VENOGRAPHY IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY-EMBOLISM AND ABNORMAL PERFUSION SCANS. Thrombosis and Haemostasis. 328-328. 1983
- PULMONARY ANGIOGRAPHY, VENTILATION SCANNING AND VENOGRAPHY IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY-EMBOLISM AND ABNORMAL PERFUSION SCANS. Clinical Research. A417-A417. 1983
- THE REGULATION OF PLATELET ENDOTHELIAL CELL-ADHESION BY 2 ARACHIDONIC-ACID METABOLITES. Thrombosis and Haemostasis. 190-190. 1983
- A PROSPECTIVE-STUDY OF VENTILATION-PERFUSION LUNG-SCANNING AND PULMONARY ANGIOGRAPHY IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY-EMBOLISM. Chest. 222-223. 1982
- EXERCISE-INDUCED MYOCARDIAL ISCHEMIA EFFECTS ON ACTIVATION OF PLATELETS AND BLOOD-COAGULATION. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 192-192. 1982
- EXERCISE-INDUCED MYOCARDIAL ISCHEMIA EFFECTS ON ACTIVATION OF PLATELETS AND BLOOD-COAGULATION. Clinical Research. A485-A485. 1982
- OBJECTIVE DIAGNOSIS OF ACUTE RECURRENT DEEP-VEIN THROMBOSIS BY COMBINED NON-INVASIVE TESTING AND VENOGRAPHY. Clinical Research. A504-A504. 1982
- PLATELET SURVIVAL AND PLASMA BETATHROMBOGLOBULIN AFTER HETEROGRAFT MITRAL-VALVE REPLACEMENT - EFFECT OF SULOCTIDIL. Circulation. 320-320. 1982
- A RANDOMIZED CLINICAL-TRIAL OF TITRATED DOSE SUBCUTANEOUS HEPARIN VERSUS WARFARIN IN THE LONG-TERM TREATMENT OF PATIENTS WITH VENOUS THROMBOSIS. Thrombosis and Haemostasis. 93-93. 1981
- BETATHROMBOGLOBULIN AND FIBRINOPEPTIDE-A IN EXERCISE-INDUCED MYOCARDIAL ISCHEMIA. Thrombosis and Haemostasis. 197-197. 1981
- Heparin Associated Thrombocytopenia Is Not A Typical Drug Induced Thrombocytopenia. Thrombosis and Haemostasis. 215-215. 1981
- PLASMA AND URINE BETATHROMBOGLOBULIN CONCENTRATION IN DEEP-VEIN THROMBOSIS. Thrombosis and Haemostasis. 169-169. 1981
- PLATELET SURVIVAL-TIME AND BETA-THROMBOGLOBULIN IN CARDIAC-VALVE REPLACEMENT. American Journal of Cardiology. 498-498. 1981
- THE CONTRIBUTION OF INCREASED FIBRINOLYSIS INDUCED BY INTERMITTENT PNEUMATIC COMPRESSION OF THE LEGS IN THE PREVENTION OF DEEP-VEIN THROMBOSIS. Thrombosis and Haemostasis. 191-191. 1981
- THE EFFECT OF ANTI-PLATELET DRUGS ON PLATELET SURVIVAL-TIME AND BETATHROMBOGLOBULIN IN CORONARY-ARTERY DISEASE. Thrombosis and Haemostasis. 192-192. 1981
- THE USE OF NON-INVASIVE TESTING AND VENOGRAPHY FOR THE DIAGNOSIS OF ACUTE RECURRENT DEEP-VEIN THROMBOSIS. Thrombosis and Haemostasis. 168-168. 1981
- THROMBOXANE B2 AND BETATHROMBOGLOBULIN IN SYMPTOMATIC CORONARY-ARTERY DISEASE. Thrombosis and Haemostasis. 268-268. 1981
- AN EVALUATION OF THE RADIOIMMUNOASSAY FOR FRAGMENT-E IN THE DIAGNOSIS OF VENOUS THROMBOSIS IN CLINICALLY SYMPTOMATIC PATIENTS. Circulation. 167-167. 1980
- CALF AND THIGH COMPRESSION TO PREVENT VENOUS THROMBOSIS (VT) IN INTRA-CRANICAL DISEASE (ICD). Circulation. 337-337. 1980
- CLINICAL-TRIAL OF LOW-DOSE HEPARIN FOR THE PREVENTION OF STROKE PROGRESSION. Circulation. 21-21. 1980
- EVALUATION OF GAMMA-FUNCTION CALCULATION OF PLATELET SURVIVAL-TIME (PST). Circulation. 277-277. 1980
- PLASMA BETATHROMBOGLOBULIN (BTG) AND SERUM FRAGMENT-E (FGE) IN ACUTE PARTIAL STROKE. Circulation. 119-119. 1980
- REPLACEMENT OF VENOGRAPHY IN SUSPECTED VENOUS THROMBOSIS BY IMPEDANCE PLETHYSMOGRAPHY AND FIBRINOGEN-I-125 LEG SCANNING. Circulation. 336-336. 1980
- THROMBOTIC THROMBOCYTOPENIC PURPURA - MECHANISM FOR EFFECTIVENESS OF PLASMAPHORESIS. Clinical Research. A299-A299. 1979
- COMPARATIVE EFFECTS OF SODIUM AND CALCIUM HEPARIN ON PLASMA HEPARIN CONCENTRATION, PARTIAL THROMBOPLASTIN TIME, PLATELET COUNT AND BLEEDING. Circulation. 206-206. 1978
- NEGATIVE CORRELATION BETWEEN PLATELET SURVIVAL, BETA-THROMBOGLOBULIN AND PLATELET AGGREGATE RATIO IN PATIENTS WITH CORONARY-ARTERY DISEASE. Circulation. 116-116. 1978
- PREVENTION OF VENOUS THROMBOSIS BY INTERMITTENT CALF COMPRESSION IN PATIENTS WITH STROKES OR AFTER NEUROSURGERY. Circulation. 118-118. 1977
-
journal articles
- Causes of death in patients with atrial fibrillation anticoagulated with rivaroxaban: a pooled analysis of XANTUS. Europace. 26:euae183. 2024
- Clinical Outcomes in Older Patients with Atrial Fibrillation: Insights from the GARFIELD-AF Registry. American Journal of Medicine. 137:128-136.e13. 2024
- Comparing U.S. and Canadian treatment patterns on venous thromboembolism outcomes in the GARFIELD-VTE registry. Thrombosis Research. 232:123-132. 2023
- Country and health expenditure are major predictors of withholding anticoagulation in atrial fibrillation patients at high risk of stroke. Open Heart. 10:e002506-e002506. 2023
-
Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the
GARFIELD‐AF registry. Diabetes, Obesity and Metabolism. 25:3040-3053. 2023 - GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. Clinical Research in Cardiology. 112:759-771. 2023
- Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry. Open Heart. 10:e002275-e002275. 2023
- Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry. Healthcare (Switzerland). 11:638-638. 2023
- 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. Thrombosis Research. 222:31-39. 2023
- Revisiting RECORD4. The Lancet. 400:2047-2048. 2022
- Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF. Open Heart. 9:e002038-e002038. 2022
- Corrigendum to “Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE” [Thromb. Res. 2020 Jul; 191:103–112]. Thrombosis Research. 216:129-129. 2022
- Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. The Lancet Haematology. 9:e594-e604. 2022
- GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. European Heart Journal - Quality of Care and Clinical Outcomes. 8:214-227. 2022
- Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE. Journal of Thrombosis and Haemostasis. 20:366-374. 2022
- Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. Journal of the American Medical Association (JAMA). 327:129-129. 2022
- Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. BMJ Open. 12:e049933-e049933. 2022
- Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD‐VTE. Journal of Thrombosis and Haemostasis. 19:3031-3043. 2021
- Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. The BMJ. 375:e066450-e066450. 2021
- Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry. Journal of Thrombosis and Haemostasis. 19:2322-2334. 2021
- The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. Thrombosis Research. 203:155-162. 2021
- Comparative effectiveness of oral anticoagulants in everyday practice. Heart. 107:962-970. 2021
- Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies. Research and Practice in Thrombosis and Haemostasis. 5:426-438. 2021
- Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Advances. 5:1081-1091. 2021
- Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE. Research and Practice in Thrombosis and Haemostasis. 5:326-341. 2021
-
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the
XANTUS real‐world prospective study. Clinical Cardiology. 43:1405-1413. 2020 - Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA network open. 3:e2022886-e2022886. 2020
- New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 6:301-309. 2020
- Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. Journal of Thrombosis and Thrombolysis. 50:267-277. 2020
- Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thrombosis Research. 191:103-112. 2020
- Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. International Journal of Stroke. 15:308-317. 2020
- Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. Journal of the American Heart Association. 9:e009530. 2020
- Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. JAMA network open. 3:e200107-e200107. 2020
- The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. Europace. 22:195-204. 2020
- International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). Thrombosis Journal. 17:7. 2019
- Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. American Journal of Medicine. 132:1431-1440.e7. 2019
- Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients. Journal of Thrombosis and Haemostasis. 17:1694-1706. 2019
- Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. Thrombosis and Haemostasis. 119:1675-1685. 2019
- Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. Thrombosis and Haemostasis. 119:1365-1372. 2019
- Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal. 213:35-46. 2019
- Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA cardiology. 4:526-526. 2019
- Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry. Clinical Cardiology. 42:553-560. 2019
- Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 5:64-69. 2019
- Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. American Journal of Medicine. 132:498-504. 2019
- Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 5:70-79. 2019
- XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. Thrombosis Research. 176:125-132. 2019
- Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. European Journal of Internal Medicine. 61:29-33. 2019
- Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. Europace. 21:421-427. 2019
- Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. Circulation. 139:787-798. 2019
- Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry. Journal of the American Heart Association. 8:e010510. 2019
- Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thrombosis and Haemostasis. 119:319-327. 2019
- XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egyptian Heart Journal. 70:307-313. 2018
-
Predictive value of venous thromboembolism (
VTE )‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients withVTE : results of theXALIA study. British Journal of Haematology. 183:457-465. 2018 - Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal. 70:828-835. 2018
- Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. Journal of Thrombosis and Thrombolysis. 46:339-345. 2018
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine. 379:1118-1127. 2018
- Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. American Journal of Medicine. 131:933-938.e1. 2018
- Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology. 72:141-153. 2018
- Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. Europace. 20:e87-e95. 2018
- Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. Thrombosis Research. 163:132-137. 2018
- Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal. 39:464-473. 2018
- Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE. 13:e0191592-e0191592. 2018
- Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 7:e017157-e017157. 2017
- International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal. 194:132-140. 2017
- Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. Journal of Thrombosis and Haemostasis. 15:1913-1922. 2017
- A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. Current Medical Research and Opinion. 33:1717-1723. 2017
- Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Therapeutic Advances in Cardiovascular Disease. 11:243-256. 2017
- Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thrombosis Research. 155:23-27. 2017
- Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 7:e014579-e014579. 2017
- Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 103:307-314. 2017
- Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thrombosis and Haemostasis. 117:1841-1847. 2017
- Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice. Orthopedic Research and Reviews. Volume 9:1-11. 2017
- Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). Thrombosis and Haemostasis. 116:1172-1179. 2016
- Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal. 37:2882-2889. 2016
- Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy. Clinical Cardiology. 39:565-569. 2016
- Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists. British Journal of Haematology. 174:610-623. 2016
- XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal. 37:1145-1153. 2016
- Real life studies and good clinical practice – Authors' reply. The Lancet Haematology. 3:e160-e161. 2016
- Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions. British Journal of Clinical Pharmacology. 81:724-734. 2016
- Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice. Clinical and Applied Thrombosis/Hemostasis. 22:138-146. 2016
- Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thrombosis and Haemostasis. 116:544-553. 2016
- Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE. 11:e0164076-e0164076. 2016
- Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. The Lancet Haematology. 3:e12-e21. 2016
- Spotlight on real-world evidence for the treatment of DVT: XALIA. Thrombosis and Haemostasis. 116:S41-S49. 2016
- The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study. Vascular Health and Risk Management. 12:209-209. 2016
- Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014. Clinical Therapeutics. 37:2506-2514.e4. 2015
- Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings. Journal of Thrombosis and Haemostasis. 13:1597-1605. 2015
- Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. New England Journal of Medicine. 373:823-833. 2015
- Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table 1. European Heart Journal, Supplement. 17:D21-D28. 2015
- Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. Journal of Thrombosis and Haemostasis. 13:1028-1035. 2015
- Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. Current Orthopaedic Practice. 26:299-305. 2015
- Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation. Cardiovascular Quality and Outcomes. 8:S12-S20. 2015
- XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thrombosis Journal. 12:16. 2014
- Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. Expert Review of Cardiovascular Therapy. 12:963-976. 2014
- Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery. Annals of Surgery. 259:1073-1079. 2014
- A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thrombosis and Haemostasis. 111:94-102. 2014
- Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vascular Health and Risk Management. 10:157-157. 2014
- Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). Thrombosis and Haemostasis. 112:213-225. 2014
- External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thrombosis and Haemostasis. 112:692-699. 2014
- Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vascular Health and Risk Management. 10:101-101. 2014
- Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. Therapeutics and Clinical Risk Management. 10:197-197. 2014
- XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vascular Health and Risk Management. 10:425-425. 2014
- Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. Journal of Thrombosis and Haemostasis. 11:1443-1448. 2013
- Venous thromboembolism management: where do novel anticoagulants fit?. Current Medical Research and Opinion. 29:783-790. 2013
- Combined Modalities in Surgical Patients. Clinical and Applied Thrombosis/Hemostasis. 19:177-177. 2013
- Cost-Effectiveness of Prevention and Treatment of VTE. Clinical and Applied Thrombosis/Hemostasis. 19:225-229. 2013
- Critical Care Medical Patients. Clinical and Applied Thrombosis/Hemostasis. 19:171-172. 2013
- Diagnosis and Anticoagulant Treatment. Clinical and Applied Thrombosis/Hemostasis. 19:187-198. 2013
- Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery – the SAVE-HIP3 study. The Bone & Joint Journal. 95-B:459-466. 2013
- General, Vascular, Bariatric, and Plastic Surgical Patients. Clinical and Applied Thrombosis/Hemostasis. 19:122-133. 2013
- Gynecology and Obstetrics. Clinical and Applied Thrombosis/Hemostasis. 19:135-141. 2013
- Heparin-Induced Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis. 19:208-214. 2013
- Inferior Vena Cava Filters. Clinical and Applied Thrombosis/Hemostasis. 19:204-205. 2013
- Introduction. Clinical and Applied Thrombosis/Hemostasis. 19:118-120. 2013
- Medical Patients. Clinical and Applied Thrombosis/Hemostasis. 19:163-171. 2013
- Neurosurgery. Clinical and Applied Thrombosis/Hemostasis. 19:161-163. 2013
- Orthopedic Surgery and Trauma. Clinical and Applied Thrombosis/Hemostasis. 19:141-160. 2013
- Patients With Cancer. Clinical and Applied Thrombosis/Hemostasis. 19:172-176. 2013
- Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation. Clinical and Applied Thrombosis/Hemostasis. 19:221-225. 2013
- Prevention and treatment of venous thromboembolism--International Consensus Statement.. International Angiology. 32:111-260. 2013
- Prevention of Postthrombotic Syndrome. Clinical and Applied Thrombosis/Hemostasis. 19:219-221. 2013
- Superficial Vein Thrombosis. Clinical and Applied Thrombosis/Hemostasis. 19:214-218. 2013
- Surgical Thrombectomy. Clinical and Applied Thrombosis/Hemostasis. 19:205-206. 2013
- The Problem and the Need for Prevention. Clinical and Applied Thrombosis/Hemostasis. 19:121-122. 2013
- Thrombolytic Therapy. Clinical and Applied Thrombosis/Hemostasis. 19:198-204. 2013
- Thrombophilia. Clinical and Applied Thrombosis/Hemostasis. 19:177-187. 2013
- Treatment for Patients With Cancer. Clinical and Applied Thrombosis/Hemostasis. 19:206-208. 2013
- Urologic Surgery. Clinical and Applied Thrombosis/Hemostasis. 19:133-134. 2013
- Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Thrombosis and Haemostasis. 110:1152-1163. 2013
- Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE. 8:e63479-e63479. 2013
- Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study. Stroke. 44:249-251. 2013
- Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?. Journal of Thrombosis and Haemostasis. 10:2621-2624. 2012
- Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation. Circulation. 126:2381-2391. 2012
- The effects of rivaroxaban on the complications of surgery after total hip or knee replacement. The Bone & Joint Journal. 94-B:1573-1578. 2012
- Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. Therapeutic Advances in Hematology. 3:309-323. 2012
- Expert interview: J-ROCKET AF. Therapeutic Research. 33:959-960. 2012
- Thromboprophylaxis in Patients Receiving Chemotherapy. New England Journal of Medicine. 366:1839-1840. 2012
- Prevention of Venous Thromboembolism After Hip or Knee Arthroplasty. Journal of Arthroplasty. 27:659-666.e5. 2012
- Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE‐HIP1, SAVE‐HIP2 and SAVE‐KNEE. Journal of Thrombosis and Haemostasis. 10:822-832. 2012
- Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer. New England Journal of Medicine. 366:601-609. 2012
- Rivaroxaban for the prevention and treatment of venous thromboembolism. Fundamental and Clinical Pharmacology. 26:33-38. 2012
- International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). American Heart Journal. 163:13-19.e1. 2012
- Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis. 108:876-886. 2012
- Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vascular Health and Risk Management. 8:363-363. 2012
- Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thrombosis and Haemostasis. 107:1027-1034. 2012
- Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. Chest. 140:706-714. 2011
- Response to “Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban”. Journal of Clinical Pharmacology. 51:1122-1123. 2011
- The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology. 27:S1-S59. 2011
- The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology. 27:208-221. 2011
- Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood. 117:2089-2092. 2011
- Factors at Admission Associated With Bleeding Risk in Medical Patients. Chest. 139:69-79. 2011
- Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thrombosis and Haemostasis. 105:444-453. 2011
- Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation. Thrombosis and Haemostasis. 105:586-596. 2011
- Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. Journal of Thrombosis and Haemostasis. 8:2369-2376. 2010
- Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility. ACP journal club. 153:8-8. 2010
- Extended thromboprophylaxis: defining the case, refining the approach. European Journal of Haematology. 85:4-11. 2010
- Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2). Journal of Thrombosis and Haemostasis. 8:714-721. 2010
- Author’s reply. The Bone & Joint Journal. 92-B:468-468. 2010
- A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thrombosis and Haemostasis. 104:1150-1157. 2010
- The cost‐effectiveness of computer‐assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study. Journal of Thrombosis and Haemostasis. 7:1482-1490. 2009
- Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement (Journal of Bone and Joint Surgery - Series B (2009) 91, (636-644)). Journal of Bone and Joint Surgery: British Volume. 91:1120. 2009
- Rivaroxaban versus enoxaparin after total knee arthroplasty – Authors' reply. The Lancet. 374:683-683. 2009
- Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.. Current Opinion in Drug Discovery and Development. 12:497-508. 2009
- Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. British Journal of Haematology. 146:142-149. 2009
- Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery: British Volume. 91B:636-644. 2009
- Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. The Bone & Joint Journal. 91-B:636-644. 2009
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. The Lancet. 373:1673-1680. 2009
- AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose-ranging study. Journal of Thrombosis and Haemostasis. 7:566-572. 2009
- Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagulation and Fibrinolysis. 20:114-121. 2009
- Postoperative Low‐Molecular‐Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology. 32:378-382. 2009
- A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thrombosis and Haemostasis. 101:487-494. 2009
- A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thrombosis and Haemostasis. 101:68-76. 2009
- Clinical benefits of rivaroxaban for VTE prevention after elective hip or knee replacement surgery. European Journal of Hospital Pharmacy: Science and Practice. 15:34-36. 2009
- Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 112:4432-4436. 2008
- The top 4 advances in antithrombotic care in the last year. Thrombosis Research. 123:S2-S6. 2008
- Dr. Lassen and colleagues reply. New England Journal of Medicine. 359:2175-2176. 2008
- Rivaroxaban for Thromboprophylaxis Reply. New England Journal of Medicine. 359:2175-2176. 2008
-
A multicentre randomised clinical endpoint study of
parma 5 computer‐assisted oral anticoagulant dosage. British Journal of Haematology. 143:274-283. 2008 - Perioperative Bridging Therapy With Unfractionated Heparin or Low-Molecular-Weight Heparin in Patients With Mechanical Prosthetic Heart Valves on Long-Term Oral Anticoagulants (from the REGIMEN Registry). American Journal of Cardiology. 102:883-889. 2008
- Warfarin replacements: Mechanisms underlying emerging agents. Canadian Journal of Cardiology. 24:56C-60C. 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty. New England Journal of Medicine. 358:2776-2786. 2008
- Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns. CANADIAN MEDICAL ASSOCIATION JOURNAL. 178:1571-1572. 2008
- An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. Journal of Thrombosis and Haemostasis. 6:935-943. 2008
- Drug Reimbursement Policies in Canada—Need for Improved Access to Critical Therapies. Annals of Pharmacotherapy. 42:869-873. 2008
- SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery. Journal of the American College of Cardiology. 51:1498-1504. 2008
- Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit. European Heart Journal, Supplement. 10:C1-C7. 2008
- Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. Journal of Thrombosis and Haemostasis. 6:457-463. 2008
- New oral anticoagulants in atrial fibrillation. European Heart Journal. 29:155-165. 2008
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery. Clinical Pharmacokinetics. 47:203-216. 2008
- Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin. ACP journal club. 147:671-671. 2007
- In response. Annals of Internal Medicine. 147:671. 2007
- Bridging therapy in patients on long‐term oral anticoagulants who require surgery: the Prospective Peri‐operative Enoxaparin Cohort Trial (PROSPECT). Journal of Thrombosis and Haemostasis. 5:2211-2218. 2007
- Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double‐blind comparison. Journal of Thrombosis and Haemostasis. 5:1854-1861. 2007
- Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients. Chest. 132:936-945. 2007
- A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. Journal of Thrombosis and Haemostasis. 5:1660-1665. 2007
- Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. Canadian Family Physician. 53:1177-1184. 2007
- Early Recovery and Functional Outcome are Related with Causal Stroke Subtype: Data from the Tinzaparin in Acute Ischemic Stroke Trial. Journal of Stroke and Cerebrovascular Diseases. 16:180-184. 2007
- Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. Journal of Thrombosis and Haemostasis. 5:1431-1437. 2007
- Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases. Arteriosclerosis, Thrombosis and Vascular Biology. 27:1238-1247. 2007
- Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. Vascular Medicine. 12:123-127. 2007
- Stroke severity, early recovery and outcome are each related with clinical classification of stroke: Data from the ‘Tinzaparin in Acute Ischaemic Stroke Trial’ (TAIST). Journal of the Neurological Sciences. 254:54-59. 2007
- Brief Communication: Preoperative Anticoagulant Activity after Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin. ACP journal club. 146:184-184. 2007
- Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy?. Journal of Thrombosis and Haemostasis. 5:5-11. 2007
- Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thrombosis Research. 119:145-155. 2007
- Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. Thrombosis and Haemostasis. 97:931-937. 2007
- Burden of disease: Medical and economic impact of acute coronary syndromes. American Journal of Managed Care. 12:S430-S434. 2006
- Burden of disease: medical and economic impact of acute coronary syndromes.. American Journal of Managed Care. 12:S430-S434. 2006
- Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. Vascular Health and Risk Management. 2:371-378. 2006
- Prevention of venous thromboembolism in medically ill patients: a clinical update. Postgraduate Medical Journal. 82:806-809. 2006
- Clinical Efficacy and Safety of Fondaparinux: An Emphasis on Results in the Elderly. Aging Health. 2:731-743. 2006
- Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism. Journal of the American Medical Association (JAMA). 296:935-935. 2006
- Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study. Journal of Thrombosis and Thrombolysis. 22:31-38. 2006
-
An Evaluation of
d -Dimer in the Diagnosis of Pulmonary Embolism. ACP journal club. 144:812-812. 2006 - Clinical outcomes with unfractionated heparin or low‐molecular‐weight heparin as bridging therapy in patients on long‐term oral anticoagulants: the REGIMEN registry. Journal of Thrombosis and Haemostasis. 4:1246-1252. 2006
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine. 354:1706-1717. 2006
- Significant variation in mortality and functional outcome after acute ischaemic stroke between western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST). Journal of Neurology, Neurosurgery and Psychiatry. 77:327-333. 2006
- Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. The BMJ. 332:325-329. 2006
- A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. American Heart Journal. 151:175.e1-175.e6. 2006
- Flexibility in Administration of Fondaparinux for Prevention of Symptomatic Venous Thromboembolism in Orthopaedic Surgery. Journal of Arthroplasty. 21:36-45. 2006
- Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction. Circulation. 112:3855-3867. 2005
- Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. Journal of Thrombosis and Haemostasis. 3:2664-2670. 2005
- Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Current Opinion in Pulmonary Medicine. 4:602-608. 2005
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Journal of Thrombosis and Haemostasis. 3:2479-2486. 2005
- Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary.. Canadian Journal of Cardiology. 21:997-1006. 2005
- Multidetector-Row Computed Tomography in Suspected Pulmonary Embolism. New England Journal of Medicine. 353:630-631. 2005
- The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: An evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. American Heart Journal. 150:27-34. 2005
- The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opinion on Drug Safety. 4:707-721. 2005
- Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case–control study. Journal of Thrombosis and Haemostasis. 3:943-948. 2005
- Influence of Warfarin on Symptoms of Fatigue: Findings of a Randomized Trial. Annals of Pharmacotherapy. 39:840-842. 2005
-
A Randomized Trial of Diagnostic Strategies after Normal Proximal Vein Ultrasonography for Suspected Deep Venous Thrombosis:
d -Dimer Testing Compared with Repeated Ultrasonography. ACP journal club. 142:490-490. 2005 - Dental procedures can be undertaken without alteration of oral anticoagulant regimen. Evidence-based dentistry. 6:11-11. 2005
- Efficacy and Safety of Fixed Low-Dose Dalteparin in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized Patients. JAMA Internal Medicine. 165:341-341. 2005
- What’s New for DVT Prophylaxis for the Medically Ill. Disease-a-Month. 51:194-199. 2005
- Prevention of Venous Thromboembolism Among Hospitalized Medical Patients. Circulation. 111:e1-e3. 2005
- Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thrombosis and Haemostasis. 94:750-759. 2005
- Clinical trials of deep vein thrombosis prophylaxis in medical patients. Clinical Cornerstone. 7:16-22. 2005
- Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART Study. Journal of Thrombosis and Haemostasis. 3:28-34. 2005
- Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thrombosis and Haemostasis. 93:76-79. 2005
- Fondaparinux. The Journal of the American Academy of Orthopaedic Surgeons. 12:371-375. 2004
- Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. Journal of Thrombosis and Haemostasis. 2:1752-1759. 2004
- Surgical management of valvular heart disease 2004.. Canadian Journal of Cardiology. 20 Suppl E:7E-120E. 2004
- Single-Arm Study of Bridging Therapy With Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin. Circulation. 110:1658-1663. 2004
- Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Circulation. 110:874-879. 2004
- Epidemiology of post-operative venous thromboembolismin asian countries. International Journal of Angiology. 13:101-108. 2004
- Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points. Chest. 126:501-508. 2004
- Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin. JAMA Internal Medicine. 164:1319-1319. 2004
- Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Expert Opinion on Pharmacotherapy. 5:1373-1384. 2004
- New Antithrombotic Drugs. Laboratory Medicine. 35:360-364. 2004
- science [coagulation and hematology]: New Antithrombotic Drugs. Laboratory Medicine. 35:360-364. 2004
- Risk Factors for Venous Thromboembolism in Hospitalized Patients With Acute Medical Illness. JAMA Internal Medicine. 164:963-963. 2004
- Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. Journal of Thrombosis and Haemostasis. 2:743-749. 2004
- Correlation of Plasma Coagulation Parameters With Thromboprophylaxis, Patient Characteristics, and Outcome in the MEDENOX Study. Archives of Pathology and Laboratory Medicine. 128:519-526. 2004
- The design of venous thromboembolism prophylaxis trials: Fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. International Journal of Clinical Practice. 58:483-493. 2004
- The safety of antithrombotic therapy during pregnancy. Expert Opinion on Drug Safety. 3:113-118. 2004
- Fondaparinux (Arixtra (R)) in the future: exploring new horizons. Thrombosis and Haemostasis. 91:A20-A22. 2004
- Low-Molecular-Weight Heparin in Acute Coronary Syndromes. Cardiology. 4:111-118. 2004
- Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin. Thrombosis and Haemostasis. 92:3-12. 2004
- Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.. Surgical technology international. 13:261-267. 2004
- Clinical Relevance of Bleeding Index. Archives of Internal Medicine. 163:2794-2794. 2003
- Clinical relevance of bleeding index - In reply. JAMA Internal Medicine. 163:2794-2795. 2003
- Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders.. American Journal of Health-System Pharmacy. 60:S20-S24. 2003
- Cost-effectiveness of Newer Antiplatelet Drugs—Reply. JAMA Internal Medicine. 163:2533-2533. 2003
- Perioperative Management of Patients Receiving Oral Anticoagulants. JAMA Internal Medicine. 163:2532-2532. 2003
- Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery.. The Lancet. 362:1581. 2003
- Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery. The Lancet. 362:1582-1583. 2003
- Fondaparinux, the first selective factor Xa inhibitor. Current Opinion in Hematology. 10:327-332. 2003
- Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine. 349:631-639. 2003
- ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies (vol 325, pg 948, 2002). The BMJ. 326:1362-1362. 2003
- Unstable Angina and Non–ST-Elevation Myocardial Infarction. Circulation. 107:2640-2645. 2003
- Prevention of venous thromboembolism in medical patients with enoxaparin. Blood Coagulation and Fibrinolysis. 14:341-346. 2003
- Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis. 14:341-346. 2003
- Perioperative Management of Patients Receiving Oral Anticoagulants. JAMA Internal Medicine. 163:901-901. 2003
- Choice of low molecular weight heparins.. Journal of Thrombosis and Haemostasis. 1:598. 2003
- Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery. Journal of Thrombosis and Haemostasis. 1:383-384. 2003
- Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thrombosis and Haemostasis. 90:364-366. 2003
- Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur. Chest. 124:371S-371S. 2003
- Low molecular weight heparins in the treatment of unstable angina.. Minerva Cardioangiologica. 50:643-651. 2002
- ABC of antithrombotic therapy: Valvar heart disease and prosthetic heart valves. The BMJ. 325:1228-1231. 2002
- Do editors live up to the Sept 10, 2001, expectations?. The Lancet. 360:1606-1606. 2002
- Do editors live up to the Sept 10, 2001, expectations?. The Lancet. 360:1605-1606. 2002
- Fondaparinux versus enoxaparin for prevention of venous thromboembolism. The Lancet. 360:1605-1605. 2002
- Fondaparinux versus enoxaparin for prevention of venous thromboembolism. The Lancet. 360:1603-1604. 2002
- Use of selective factor Xa inhibitors in special populations.. American Journal of Orthopedics. 31:11-15. 2002
- ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies. The BMJ. 325:948-950. 2002
- ABC of antithrombotic therapy: Venous thromboembolism: pathophysiology, clinical features, and prevention. The BMJ. 325:887-890. 2002
- Erratum: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A rondomised double-blind trial (Lancet (May 18) (1721)). The Lancet. 360:1102. 2002
- Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>. JAMA Internal Medicine. 162:1833-1833. 2002
- Overweight and Obesity as Determinants of Cardiovascular Risk. JAMA Internal Medicine. 162:1867-1867. 2002
- Deep venous thrombosis in the medically ill.. Current hematology reports. 1:73-78. 2002
- Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. Current Opinion in Pulmonary Medicine. 8:398-404. 2002
- Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. Current Opinion in Pulmonary Medicine. 8:398-404. 2002
- Factor Xa inhibitors in the prevention and treatment of venous thromboembolism - The role of fondaparinux, first of a new class of antithrombotic agents. Today's Therapeutic Trends. 20:253-267. 2002
- Pentasaccharides. Seminars in Hematology. 39:158-171. 2002
- Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. The Lancet. 359:1721-1726. 2002
- Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. The Lancet. 359:1715-1720. 2002
- Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Expert Opinion on Pharmacotherapy. 3:575-598. 2002
- New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 166:919-924. 2002
- A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.. Journal of surgical orthopaedic advances. 11:182-188. 2002
- A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist.. Journal of surgical orthopaedic advances. 11:197-202. 2002
- Benefit of Selective Factor Inhibition. Seminars in Thrombosis and Hemostasis. 28:049-050. 2002
- Fondaparinux Sodium. Drugs. 62:1686-1687. 2002
- New Standards in Antithrombotic Therapy: Concepts, Clinical Evidence, and Applications. Seminars in Thrombosis and Hemostasis. 28:001-002. 2002
- Optimizing Prophylaxis of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis. 28:025-032. 2002
- State of the Art-A Journey through the World of Antithrombotic Therapy. Seminars in Thrombosis and Hemostasis. 28:003-012. 2002
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery. New England Journal of Medicine. 345:1305-1310. 2001
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery. New England Journal of Medicine. 345:1298-1304. 2001
- Overview of the clinical results of pentasaccharide in major orthopedic surgery.. Haematologica. 86:59-62. 2001
- Setting a standard for venous thromboembolism prophylaxis. American Journal of Health-System Pharmacy. 58:S18-S23. 2001
- Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. The Lancet. 358:702-710. 2001
- Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice. American Heart Journal. 142:S9-S15. 2001
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis. New England Journal of Medicine. 345:291-292. 2001
- A synthetic pentasaccharide for the prevention of deep-vein thrombosis - Reply. New England Journal of Medicine. 345:292-292. 2001
- Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. American Journal of Cardiology. 88:40-44. 2001
- Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes. JAMA Internal Medicine. 161:1484-1484. 2001
- Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin. American Heart Journal. 141:1025-1037. 2001
- Thromboembolism and pregnancy.. International Angiology. 20:103-109. 2001
- A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction. American Journal of Cardiology. 87:1008-1010. 2001
- Looking forward in the treatment of deep-vein thrombosis. Seminars in Hematology. 38:49-57. 2001
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement. New England Journal of Medicine. 344:619-625. 2001
- Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves. Chest. 119:220S-227S. 2001
- Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (MEDENOX) trial. American Journal of Cardiology. 86:48-52. 2000
- Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity. Circulation. 102:2726-2731. 2000
- Therapy of unstable angina with the low molecular weight heparins. Vascular Medicine. 5:217-223. 2000
- Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction. American Journal of Cardiology. 86:553-556. 2000
- Low-molecular-weight heparin in the treatment of pulmonary embolism.. Seminars in Vascular Surgery. 13:189-193. 2000
- Management of unstable angina and myocardial infarction. The Lancet. 356:1193-1194. 2000
- Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease - One-year results of the ESSENCE study. Journal of the American College of Cardiology. 36:693-698. 2000
- Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52.. Journal of the American College of Cardiology. 36:693-698. 2000
- Management of Deep Vein Thrombosis and Pulmonary Embolism. Scottish Medical Journal. 45:40-42. 2000
- Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism (vol 129, pg 1006, 1998). Annals of Internal Medicine. 132:247-247. 2000
- A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy. Thrombosis and Haemostasis. 83:849-852. 2000
- Antithrombotics and Anticoagulants in Coronary Syndromes and Stroke. Seminars in Thrombosis and Hemostasis. Volume 26:085-086. 2000
- Can we differentiate the low-molecular-weight heparins?. Clinical Cardiology. 23:4-7. 2000
- Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. Thrombosis and Haemostasis. 83:416-420. 2000
- Is lung scanning necessary in all patients with confirmed DVT?. Journal of Critical Illness. 15:74. 2000
- The use of glycoprotein IIb/IIIa receptor inhibitors in unstable angina.. Folia Cardiologica. 29:1357-1365. 1999
- Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction. Circulation. 100:1593-1601. 1999
- Effectiveness of nifedipine GITS in combination with atenolol in chronic stable angina.. Canadian Journal of Cardiology. 15:1103-1109. 1999
- Exaggerated initial response to warfarin following heart valve replacement. American Journal of Cardiology. 84:905-908. 1999
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. New England Journal of Medicine. 341:793-800. 1999
- Anticoagulants in acute coronary syndromes. American Journal of Cardiology. 84:2-6. 1999
- Antithrombotic therapy in the new millennium - The role of low-molecular-weight heparin. SAMJ - South African Medical Journal. 89. 1999
- Management strategies in unstable coronary artery disease—Current problems and future directions. Clinical Cardiology. 22:551-553. 1999
- Anticoagulation in acute ischaemic stroke: deep vein thrombosis prevention and long-term stroke outcomes - Conclusions. Blood Coagulation and Fibrinolysis. 10:S129-S130. 1999
- Building a new era in DVT management. Conclusions.. Blood Coagulation and Fibrinolysis. 10 Suppl 2:S129-S130. 1999
- Building a new era in DVT management. Introduction.. Blood Coagulation and Fibrinolysis. 10 Suppl 2:S1-S3. 1999
- Customizing our approach in deep vein thrombosis and pulmonary embolism treatment: overview of our clinical experience.. Blood Coagulation and Fibrinolysis. 10 Suppl 2:S107-S115. 1999
- From foundations to the future: Building a new era in DVT management - Proceedings of a Meeting held in Barcelona, Spain, 26-27 June 1998 - Introduction. Blood Coagulation and Fibrinolysis. 10:S1-S3. 1999
- Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis.. Thrombosis and Haemostasis. 81:879-886. 1999
- The Ten Most Commonly Asked Questions about Chronic Anticoagulant Use in Cardiology. Cardiology in Review. 7:125-126. 1999
- Venous thrombosis after THA - Reply. Orthopedics. 22:477-477. 1999
- Venous thrombosis after THA.. Orthopedics. 22:476-477. 1999
- A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. New England Journal of Medicine. 340:901-907. 1999
- Low-Molecular-Weight Heparins in Acute Unstable Coronary Artery Disease – An Update. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 29:72-75. 1999
- Prediction of Deep Vein Thrombosis after Elective Hip Replacement Surgery by Preoperative Clinical and Haemostatic Variables: The ECAT DVT Study. Thrombosis and Haemostasis. 81:879-886. 1999
- Sensitivity and Specificity of a Rapid Whole-Blood Assay for D-Dimer in the Diagnosis of Pulmonary Embolism. ACP journal club. 129:1006-1006. 1998
- Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism. ACP journal club. 129:997-997. 1998
- Prevention of Venous Thrombosis After Elective Hip Surgery. Orthopedics. 21:1275-1281. 1998
- Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves. Chest. 114:602S-610S. 1998
- Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.. American Journal of Cardiology. 82:19L-24L. 1998
- A Randomized Comparison of a Computer-Based Dosing Program with a Manual System to Monitor Oral Anticoagulant Therapy. Thrombosis Research. 91:237-240. 1998
- Clinical potential of antithrombotic drugs in coronary syndromes. American Journal of Cardiology. 82:11L-14L. 1998
- Introduction. American Journal of Cardiology. 82:1L-2L. 1998
- Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.. Canadian Journal of Cardiology. 14 Suppl E:20E-23E. 1998
- Pharmacology of the low-molecular-weight heparins. American Heart Journal. 135:S329-S335. 1998
- Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients. Circulation. 97:1702-1707. 1998
- Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].. Circulation. 97:1702-1707. 1998
- Management Strategies for a Better Outcome in Unstable Coronary Artery Disease. Clinical Cardiology. 21:314-322. 1998
- Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. The BMJ. 316:17-20. 1998
- Antithrombotic Therapy in Coronary Ischaemia: The Expanding Role of Low-Molecular-Weight Heparin. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 28:35-42. 1998
- Survey of cardiac surgeons' perceptions of the addition of ASA to warfarin for patients with mechanical heart valves.. Canadian Journal of Cardiology. 13:1162-1165. 1997
- Guidelines for Management of Left-Sided Prosthetic Valve Thrombosis: A Role for Thrombolytic Therapy 11These guidelines are the results of a Consensus Conference held during the Symposium on Prosthetic Valve Thrombosis on September 16, 1994, in Budapest, Hungary.. Journal of the American College of Cardiology. 30:1521-1526. 1997
- Successors to heparin: new antithrombotic agents.. American Heart Journal. 134:S71-S77. 1997
- A symposium: New frontiers in the management of unstable coronary artery disease - Introduction. American Journal of Cardiology. 80:E1-E1. 1997
- Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism. New England Journal of Medicine. 337:657-662. 1997
- Fragmin in Unstable Angina Pectoris or in Non-Q-Wave Acute Myocardial Infarction (the FRIC Study). American Journal of Cardiology. 80:30E-34E. 1997
- New Frontiers in the Management of Unstable Coronary Artery Disease. American Journal of Cardiology. 80:21E-24E. 1997
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease. New England Journal of Medicine. 337:447-452. 1997
- American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Etiology of stroke.. Stroke. 28:1501-1506. 1997
- Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease. Circulation. 96:61-68. 1997
- Moderate intensity adjusted-dose warfarin was more effective than low-intensity fixed dose warfarin and aspirin in preventing strokes in atrial fibrillation. Evidence-based Cardiovascular Medicine. 1:50-50. 1997
- The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. JAMA Internal Medicine. 157:1077-1081. 1997
- A double blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease "The essence trial". Heart. 77. 1997
- A comparison of compression ultrasound with color Doppler ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis. JAMA Internal Medicine. 157:765-768. 1997
- Prophylaxis of Venous Thromboembolism in Stroke Patients. Seminars in Thrombosis and Hemostasis. 23:155-157. 1997
- Safer anticoagulant therapy after heart valve replacement. Postgraduate Medicine. 101:85-94. 1997
- Low-Molecular-Weight Heparin: From the Bench to the Orthopedic Patient. Orthopedics. 20:10-13. 1997
- Low-molecular-weight heparin: from the bench to the orthopedic patient.. Orthopedics. 20 Suppl:10-13. 1997
- Antithrombotic Therapy Following Heart Valve Replacement. Thrombosis and Haemostasis. 78:382-385. 1997
- Antithrombotic therapy: the expanding role of low molecular weight heparin.. Indian Heart Journal. 49:489-492. 1997
- Low-Molecular-Weight Heparins and Unstable Angina – Current Perspectives. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 27:19-24. 1997
- The Essence Trial: Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave MI: A Double-Blind, Randomized, Parallel-Group, Multicenter Study Comparing Enoxaparin and Intravenous Unfractionated Heparin: Methods and Design.. Journal of Thrombosis and Thrombolysis. 4:271-274. 1997
- Comparison of High-Dose With Low-Dose Aspirin in Patients With Mechanical Heart Valve Replacement Treated With Oral Anticoagulant. Circulation. 94:2113-2116. 1996
- Mechanical valves. Annals of Thoracic Surgery. 62:1567-1570. 1996
- Antithrombotic therapy in atrial fibrillation.. Canadian Family Physician. 42:1341-1345. 1996
- Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. JAMA Internal Medicine. 156:851-856. 1996
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis. New England Journal of Medicine. 334:677-681. 1996
- Hirudin and thrombosis prophylaxis. The Lancet. 347:632-633. 1996
- [Antithrombotic treatment of atrial fibrillation].. Canadian Journal of Cardiology. 12 Suppl A:14A-18A. 1996
- Antithrombotic therapy in atrial fibrillation.. Canadian Journal of Cardiology. 12 Suppl A:17A-20A. 1996
- Diagnosis and treatment of deep vein thrombosis.. Surgical technology international. 5:377-381. 1996
- Low Molecular Weight Heparin and Compression Stockings in the Prevention of Venous Thromboembolism in Neurosurgery. Thrombosis and Haemostasis. 75:233-238. 1996
- Low-Molecular-Weight Heparinoid Orgaran Is More Effective Than Aspirin in the Prevention of Venous Thromboembolism After Surgery for Hip Fracture. Circulation. 93:80-84. 1996
- Management Of Venous Thromboembolism: Optimization By Clinical Trials. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 26:220-226. 1996
- New therapeutic opportunities for heparins: What does low molecular weight heparin offer?. Journal of Thrombosis and Thrombolysis. 3:145-149. 1996
- Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves. Chest. 108:371S-379S. 1995
- Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts. Chest. 108:424S-430S. 1995
- Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration.. Canadian Journal of Cardiology. 11:649-657. 1995
- Concluding remarks. European Heart Journal. 16:38-39. 1995
- DEEP VEIN THROMBOSIS PROPHYLAXIS IN THE OUTPATIENT SETTING: PREVENTING COMPLICATIONS FOLLOWING HOSPITAL DISCHARGE. Orthopedics. 18:15-17. 1995
- Deep vein thrombosis prophylaxis in the outpatient setting: preventing complications following hospital discharge.. Orthopedics. 18 Suppl:15-17. 1995
- INR reporting in Canadian medical laboratories. American Journal of Hematology. 48:237-239. 1995
- ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. The Lancet. 345:669-685. 1995
- Advances in Antithrombotic Therapy: Novel Agents. Thrombosis and Haemostasis. 74:565-571. 1995
- Management of deep vein thrombosis: Prevention and treatment. P and T. 20. 1995
- Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. Thrombosis and Haemostasis. 74:606-611. 1995
- Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.. Circulation. 90:2385-2389. 1994
- The present status of thrombolytic treatment in noncardiac disorders. Journal of Internal Medicine. 236:447-454. 1994
- Results of a Prospective Randomized Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity The STILE Trial. Annals of Surgery. 220:251-268. 1994
- Preventing Thromboembolism in Patients with Prosthetic Heart Valves. Cardiology Clinics. 12:487-493. 1994
- WARFARIN AND ASPIRIN AFTER HEART-VALVE REPLACEMENT - REPLY. New England Journal of Medicine. 330:508-509. 1994
- Warfarin and Aspirin after Heart-Valve Replacement. New England Journal of Medicine. 330:507-509. 1994
- A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. JAMA Internal Medicine. 154:49-56. 1994
- Aspirin and warfarin after heart-valve replacement. Annals of Internal Medicine. 120:3. 1994
- Closing Remarks. Cerebrovascular Diseases. 4:47-47. 1994
- A Comparison of Real-Time Compression Ultrasonography with Impedance Plethysmography for the Diagnosis of Deep-Vein Thrombosis in Symptomatic Outpatients. New England Journal of Medicine. 329:1365-1369. 1993
- A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve Replacement. New England Journal of Medicine. 329:524-529. 1993
- Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves. Chest. 102:445S-455S. 1992
- Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts Following Percutaneous Transluminal Coronary Angioplasty. Chest. 102:508S-515S. 1992
- A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke. ACP journal club. 117:353-357. 1992
- ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. The Lancet. 339:753-770. 1992
- Orgaran in the Prevention of Deep Vein Thrombosis in Stroke Patients. Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research. 22:92-98. 1992
- Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. American Journal of Surgery. 161:532-536. 1991
- Prevention of Deep Vein Thrombosis after Elective Hip Surgery. ACP journal club. 114:545-551. 1991
- Introduction. Blood Coagulation and Fibrinolysis. 14:vii-vii. 1991
- A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism. Chest. 98:1473-1479. 1990
- Use of plasminogen activators in venous thrombosis. World Journal of Surgery. 14:688-693. 1990
- Thrombolytic agents in venous thrombosis. Journal of Vascular Surgery. 12:196-197. 1990
- 14 Antithrombotic treatment of cerebrovascular disease. Best Practice and Research in Clinical Haematology. 3:781-813. 1990
- A NEW SHORT INFUSION DOSAGE REGIMEN OF RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE. Chest. 97:S168-S171. 1990
- A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease. Chest. 97:168S-171S. 1990
- Tissue Plasminogen Activator (rt-PA) vs Heparin in Deep Vein Thrombosis. Chest. 97:172S-175S. 1990
- Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.. Chest. 97:172S-175S. 1990
- Anticoagulant therapy after acute myocardial infarction. American Journal of Cardiology. 65:C20-C23. 1990
- Enoxaparin prophylaxis in elective hip surgery.. British Journal of Surgery. 556:103-107. 1990
- High-dose subcutaneous heparin for prevention of mural thrombosis after acute myocardial infarction. Cardiology Board Review. 7:75-85. 1990
- Therapy of deep vein thrombosis.. Herz. 14:341-347. 1989
- Detection of previous proximal venous thrombosis with Doppler ultrasonography and photoplethysmography. JAMA Internal Medicine. 149:2255-2257. 1989
- HEPARIN FOR MURAL THROMBOSIS IN ANTERIOR MYOCARDIAL-INFARCTION - REPLY. New England Journal of Medicine. 321:260-260. 1989
- Heparin for Mural Thrombosis in Anterior Myocardial Infarction. New England Journal of Medicine. 321:259-260. 1989
- Prevention of left ventricular mural thrombus. American Journal of Cardiology. 64:41B-43B. 1989
- HEPARIN IN THE TREATMENT OF THROMBOEMBOLIC STROKE. Annals of the New York Academy of Sciences. 556:406-415. 1989
- Heparin in the Treatment of Thromboembolic Stroke. Annals of the New York Academy of Sciences. 556:406-415. 1989
- THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE. The Lancet. 333:1215-1220. 1989
- A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. JAMA Internal Medicine. 149:771-774. 1989
- Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. JAMA Internal Medicine. 149:679-681. 1989
- Comparison of High-Dose with Low-Dose Subcutaneous Heparin to Prevent Left Ventricular Mural Thrombosis in Patients with Acute Transmural Anterior Myocardial Infarction. New England Journal of Medicine. 320:352-357. 1989
- An Evaluation of Impedance Plethysmography and 125I-Fibrinogen Leg Scanning in Patients following Hip Surgery. Thrombosis and Haemostasis. 62:830-834. 1989
- Canadian and American study of ticlopidine in thromboembolic cerebrovascular accidents. Revista Brasileira de Neurologia. 25:171-172. 1989
- Fate of the patient with chronic leg ischaemia. A review article.. Journal of Cardiovascular Surgery. 30:50-57. 1989
- The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin.. International Journal of Clinical Practice, Supplement. 65:18-23. 1989
- The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results.. Stroke. 19:1203-1210. 1988
- RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT. The Lancet. 331:1242-1245. 1988
- ALTERNATE METHODS OF HEPARIN ADMINISTRATION. Annals of Internal Medicine. 108:306-306. 1988
- Clinical Studies: Evidence for Intervention with Specific Antiplatelet Drugs in Arterial Thromboembolism. Seminars in Thrombosis and Hemostasis. 14:41-49. 1988
- Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke.. British Journal of Surgery. 543:85-86. 1988
- Subcutaneous versus continuous intravenous heparin for acute deep vein thrombosis. Cardiology Board Review. 5:103-114. 1988
- Adjusted Subcutaneous Heparin or Continuous Intravenous Heparin in Patients with Acute Deep Vein Thrombosis. ACP journal club. 107:441-441. 1987
- Effect of nafazatrom on platelet function and release: Relationship to symptomatic episodes in patients with peripheral vascular disease. American Heart Journal. 113:1133-1137. 1987
- HEPARIN IN ACUTE PARTIAL STABLE STROKE - RESPONSE. Annals of Internal Medicine. 106:782-782. 1987
- Low-Molecular-Weight Heparin and Deep-Vein Thrombosis. New England Journal of Medicine. 316:949-949. 1987
- DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE. The Lancet. 329:523-526. 1987
- Intravenous Heparin for the Prevention of Stroke Progression in Acute Partial Stable Stroke: A Randomized Controlled Trial. Annals of Internal Medicine. 105:825-825. 1986
- Intravenous heparin for the prevention of stroke progression in acute partial stable stroke.. ACP journal club. 105:825-828. 1986
- A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery. New England Journal of Medicine. 315:925-929. 1986
- An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. Thrombosis Research. 39:173-181. 1985
- A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke.. Stroke. 16:416-424. 1985
- Diagnostic Efficacy of Impedance Plethysmography for Clinically Suspected Deep-Vein Thrombosis. ACP journal club. 102:21-21. 1985
- Outcome of abnormal impedance plethysmography results in patients with proximal-vein thrombosis: Frequency of return to normal. Thrombosis Research. 36:259-263. 1984
- Evaluation of a Commercial Kit for the Radioimmunoassay of Fibrinopeptide A. Journal of Immunoassay and Immunochemistry. 5:245-266. 1984
- Effect of suloctidil on platelet function in patients with shortened platelet. Survival time. Thrombosis Research. 35:397-406. 1984
- Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia.. Translational Research. 103:606-612. 1984
- Anticoagulant therapy following acute myocardial infarction. Part I. Incidence of and factors predisposing to thromboembolism associated with acute myocardial infarction.. Modern concepts of cardiovascular disease. 52:45-48. 1983
- Pulmonary Angiography, Ventilation Lung Scanning, and Venography for Clinically Suspected Pulmonary Embolism with Abnormal Perfusion Lung Scan. ACP journal club. 98:891-891. 1983
- The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge.. Circulation. 67:901-906. 1983
- Platelet tests and antiplatelet drugs in coronary artery disease.. Circulation. 67:500-504. 1983
- ANTICOAGULANT-THERAPY FOLLOWING ACUTE MYOCARDIAL-INFARCTION .2. ANTI-THROMBOTIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION. Modern concepts of cardiovascular disease. 52:49-51. 1983
- Dipyridamole disposition after chronic administration: Effect of aspirin. Thrombosis Research. 29:137-143. 1983
- The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Thrombosis Research. 29:125-139. 1983
- Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis. New England Journal of Medicine. 307:1676-1681. 1982
- High-performance liquid chromatographic determination of dipyridamole. Journal of Chromatography - Biomedical Applications. 231:216-221. 1982
- Platelet release and thromboxane synthesis in symptomatic coronary artery disease.. Circulation. 66:327-333. 1982
- Subcutaneous Heparin for Venous Thrombosis. New England Journal of Medicine. 307:56-58. 1982
- Plasma betathromboglobulin and serum fragment E in acute partial stroke. British Journal of Haematology. 50:327-334. 1982
- The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis. Blood. 59:346-350. 1982
- Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.. Progress in Clinical and Biological Research. 89:31-62. 1982
- Chemistry, Measurement, and Clinical Significance of Platelet Specific Proteins. Critical Reviews in Clinical Laboratory Sciences. 18:183-211. 1982
- Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: Natural history of acute partial stroke and stroke-in-evolution. Journal of Cerebral Blood Flow and Metabolism. 2:267. 1982
- Platelet Consumption in Cardiovascular Disease. Seminars in Thrombosis and Hemostasis. 8:161-185. 1982
- SUBCUTANEOUS HEPARIN FOR VENOUS THROMBOSIS - REPLY. New England Journal of Medicine. 307:57-58. 1982
- Plasma and urine beta-thromboglobulin concentration in patients with deep vein thrombosis. Blood. 58:693-698. 1981
- Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis.. Circulation. 64:622-625. 1981
- Antiplatelet Therapy. Clinics in Haematology. 10:497-520. 1981
- Practical Application of125I-Fibrinogen Leg Scanning. Critical Reviews in Clinical Laboratory Sciences. 14:241-255. 1981
- Replacement of Venography in Suspected Venous Thrombosis by Impedance Plethysmography and125I-Fibrinogen Leg Scanning. ACP journal club. 94:12-12. 1981
- The use of the evacuated blood collection tube in the determination of plasma betathromboglobulin. Thrombosis Research. 20:693-695. 1980
- VENOUS THROMBOEMBOLISM ASSOCIATED WITH GYNECOLOGIC SURGERY. Clinical Obstetrics and Gynecology. 23:209-241. 1980
- Beta-Thromboglobulin Radioimmunoassay. A Laboratory Characterization and Evaluation. Journal of Immunoassay and Immunochemistry. 1:211-227. 1980
- Clinical trial of low-dose heparin for the prevention of stroke progression. Circulation. 62. 1980
- Plasma beta-thromboglobulin: differentiation between intravascular and extravascular platelet destruction. Blood. 54:1192-1196. 1979
- The Effect of Antiplatelet Drugs on Plasma Betathromboglobulin in Coronary Artery Disease. Thrombosis and Haemostasis. 42:059-059. 1979
- When and how to use heparin prophylaxis and treatment.. Geriatrics: better medicine for midlife and beyond. 34:59-70. 1979
- Heparin. Nova Scotia Medical Bulletin. 58:25-29. 1979
- Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. Thrombosis Research. 15:611-616. 1979
- Prophylaxis and Therapy of Venous Thromboembolism. Critical Reviews in Clinical Laboratory Sciences. 10:247-274. 1979
- The effect of contrast media, 125iodine-labelled fibrinogen, heparin and aspirin on plasma BTG concentration. Thrombosis and Haemostasis. 42:304. 1979
- The value of adding impedance plethysmography to 125I-fibrinogen leg scanning for the detection of deep vein thrombosis in high risk surgical patients: A comparative study between patients undergoing general surgery and hip surgery. Thrombosis Research. 15:227-234. 1979
- Impedance plethysmography: the relationship between venous filling and sensitivity and specificity for proximal vein thrombosis.. Circulation. 58:898-902. 1978
- PLATELET SUPPRESSIVE THERAPY. British Medical Bulletin. 34:183-190. 1978
- [Pathogenesis of thrombosis].. L'union medicale du Canada. 107:155-161. 1978
- [Physical methods of prevention of venous thromboemboli].. L'union medicale du Canada. 107:227-231. 1978
- [Venous thromboemboli].. L'union medicale du Canada. 107:238-241. 1978
- ARTERIAL THROMBO EMBOLISMS. L'union medicale du Canada. 107:198-203. 1978
- Comparative effects of sodium and calcium heparin on plasma heparin concentration, partial thromboplastin time, platelet count and bleeding. Circulation. 58. 1978
- MECHANICAL METHODS OF PROPHYLAXIS AGAINST VENOUS THROMBO EMBOLISMS. L'union medicale du Canada. 107:227-231. 1978
- Paramyxovirus-induced platelet aggregation. Requirement for neuraminic acid receptors on platelets.. Laboratory Investigation. 37:150-157. 1977
- Combined Use of Leg Scanning and Impedance Plethysmography in Suspected Venous Thrombosis. New England Journal of Medicine. 296:1497-1500. 1977
- Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology. 27:435-435. 1977
- Impedance plethysmography using the occlusive cuff technique in the diagnosis of venous thrombosis.. Circulation. 53:696-700. 1976
- Proceedings: Failure of aspirin and dipyridamole to influence the incidence of leg scan detected venous thrombosis after elective hip surgery.. Thrombosis and Haemostasis. 34:564. 1975
- Thrombolysis with a Combination of Small Doses of Streptokinase and Full Doses of Heparin. Seminars in Thrombosis and Hemostasis. 2:14-32. 1975
- Interaction between Viruses and Platelets: Requirement of Haemolytic Activity for Platelet Aggregation Induced by Paramyxoviruses. Journal of General Virology. 21:205-213. 1973
- Effect of Newcastle disease virus on human or rabbit platelets. Aggregation and loss of constituents.. Laboratory Investigation. 28:575-583. 1973
- Effectin vitroon platelet function of two compounds developed from the pyrimido-pyrimidines. Journal of Clinical Pathology - Clinical Molecular Pathology. 25:427-432. 1972
- Urokinase Therapy: Dosage Schedules and Coagulant Side Effects. British Journal of Haematology. 22:567-577. 1972
- Platelet electrophoresis: effect of defibrination by ancrod (Arvin). Cardiovascular Research (CVR). 6:101-108. 1972
- In‐Vitro Studies with Ancrod (‘Arvin’). British Journal of Haematology. 20:217-224. 1971
- Treatment of Hypertension with Clonidine. The BMJ. 3:440-442. 1970
- Effect of RA233 on Platelet Function In Vitro. The BMJ. 2:83-86. 1970
- Effect of gaboon viper (Bitis gabonica) venom on blood coagulation, platelets, and the fibrinolytic enzyme system. Journal of Clinical Pathology - Clinical Molecular Pathology. 22:312-316. 1969
- Clinical trial of deglydyrrhizinized liquorice in gastric ulcer.. Gut. 10:299-302. 1969
- CHANGES IN PLATELET BEHAVIOUR DURING ARVIN THERAPY. The Lancet. 293:644-647. 1969
- CEPHALORIDINE TOXICITY. The Lancet. 291:47-48. 1968
- Idiopathic gangrene in African children.. The BMJ. 3:646-648. 1967
- Enhancement of the Activity of Optimum Concentrations of Urokinase by the Venom of Echis carinata. Nature. 211:989-990. 1966
- Studies on East African Snakes. Scottish Medical Journal. 11:168-175. 1966
- Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects.. Gut. 6:591-594. 1965
- The anticoagulant action of puff adder (B. arietans) venom.. East African Medical Journal. 42:565-574. 1965